The U.S. Food and Drug Administration (FDA) implemented a label revision for Metformin Hydrochloride on 2026-06-26. This update specifically addresses the indication and usage section of the drug's prescribing information. The revised label now clearly states that Metformin Hydrochloride Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Background
Metformin Hydrochloride is an oral antihyperglycemic agent widely recognized as a first-line therapy for type 2 diabetes mellitus. This chronic metabolic disorder is characterized by high blood sugar levels, affecting millions worldwide and leading to serious health complications if not properly managed. The drug has a long history of use, and this label update serves to consolidate and clarify its approved therapeutic application for healthcare providers and patients.
What this means
This label revision provides enhanced clarity and precise guidance for healthcare professionals prescribing Metformin Hydrochloride. It explicitly reinforces the drug's established and critical role as a foundational treatment for improving glycemic control. By specifying its use as an adjunct to diet and exercise, the update emphasizes a comprehensive approach to managing type 2 diabetes mellitus in both adult and pediatric patient populations. This ensures that prescribing information remains current and unambiguous for clinical practice.
Source
The updated label information for Metformin Hydrochloride was published by the FDA on 2026-06-26. This revision is available on the DailyMed website, hosted by the National Library of Medicine (NLM), an official source for drug label information, under the specific set ID 552df462-6dcb-e6f2-e063-6294a90aacfe.